What is Kypha?
Kypha operates at the intersection of biotechnology and clinical diagnostics, focusing on the development of advanced biomarker testing systems. The company provides essential insights into complement proteins, which are vital for understanding immune-related conditions. Through its proprietary technology, Kypha enables both multiplex analysis and single analyte measurement, offering healthcare providers and clinical labs the precision required for rapid, data-backed treatment decisions. Their service portfolio, which includes custom assay development and exploratory biomarker analysis, is designed to meet rigorous regulatory standards, ensuring that therapeutic development and patient care are supported by high-fidelity diagnostic data.
How much funding has Kypha raised?
Kypha has raised a total of $6.9M across 3 funding rounds:
Private Equity
$750K
Debt
$2.1M
Series A
$4M
Private Equity (2013): $750K, investors not publicly disclosed
Debt (2015): $2.1M, investors not publicly disclosed
Series A (2018): $4M, investors not publicly disclosed
Key Investors in Kypha
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Kypha?
With the successful completion of this major strategic investment, Kypha is well-positioned to accelerate its market penetration and expand its diagnostic capabilities. The company is expected to focus on scaling its assay development infrastructure and deepening its footprint within the healthcare provider ecosystem. By prioritizing the integration of its immune insights platform into broader clinical workflows, Kypha aims to standardize the use of real-time protein monitoring in therapeutic decision-making. Future growth will likely center on enhancing its regulatory-compliant service offerings and fostering strategic partnerships that leverage its unique multiplex analysis technology to address unmet needs in immune-related disease management.
See full Kypha company page
